7JN Stock Chart & Stats
€0.08
€0.00(0.00%)
At close: 4:00 PM EDT
€0.08
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)194.00
Market Cap
€56.91M
Enterprise Value€43.38M
Total Cash (Recent Filing)€4.82M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding763,437,130
10 Day Avg. Volume566
30 Day Avg. Volume194
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory ProgressMHRA approval, finalized protocols, secured sites and an appointed CRO show that POLB 001 has moved into an executable clinical stage. This reduces development friction and creates a defined path to generate human data that could support partnering and later-stage advancement.
Strong Early PharmacologyDose-dependent suppression of key cytokines provides evidence of target engagement in humans and supports the biological rationale for POLB 001. If the signal translates into cancer patients, it could strengthen differentiation and improve the asset’s partnering potential.
Low Financial LeverageA debt-free balance sheet avoids mandatory interest and principal payments while the company remains in development. This preserves more flexibility to direct available cash toward clinical programs and reduces the risk that leverage compounds the effects of ongoing operating losses.
Bears Say
Pre-revenue Loss ProfilePoolbeg has not yet generated commercial revenue to offset research and operating costs, leaving earnings dependent on future clinical progress and transactions. Persistent losses make financial performance highly sensitive to development outcomes and delay the arrival of self-funded operations.
Sustained Cash Burn And Equity ErosionContinued operating cash outflows consume the resources available for clinical development, while shrinking equity reflects cumulative losses and reduces financial flexibility. Unless partnering proceeds or new funding arrive, the company may need further external capital to sustain expansion.
Dependence On External PartnersPoolbeg’s asset-light model depends on partner interest and negotiations to fund later-stage development and commercialization. This can limit control over timing, economics and execution, and means promising clinical data may not automatically convert into durable revenue or royalties.
Poolbeg Pharma Ltd. News
7JN FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest stock price was €0.03 and its highest was €0.11 in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is €56.91M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 137 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Sep 29, 2026. The company reported -€0.004 earnings per share for the quarter.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 763,437,130 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -€0.004 in its last earnings report. Following the earnings report the stock price went up 5.714%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in DE:7JN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.46%
12-Months-Change
Fundamentals
Return on Equity
-71.28%
Trailing 12-Months
Asset Growth
-42.16%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―